Adaptive Biotechnologies ADPT 深 沪
等待开盘 06-30 09:30:00 美东时间
21.40
+0.440
+2.10%
华盛通- 最 高21.64
- 今 开21.20
- 成交量 352.44万股
- 最 低 20.73
- 昨 收 20.96
- 总市值 34.25亿
- 52周最高 21.64
- 市盈率 静 --
- 换手率 2.20%
- 52周最低 9.9551
- 委 比 -97.19%
- 总股本 1.60亿
- 历史最高 71.25
- 量 比 0.86
- 振 幅 4.34%
- 历史最低 2.28
- 每 手 1
- 风险率 2.31%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 康托·菲茨杰拉德大幅上调AMD、英特尔、迈威尔科技、美光、西部数据目标价！Applied、INIO、LFTO、Quantinuum获多家大行首予买入评级
今日重点评级关注：Evercore ISI集团：维持ProQR Therapeutics"跑赢大市"评级，目标价从5美元升至6美元；摩根士丹利：维持霍尼韦尔"标配"评级，目标价从245美元升至490美元
今天 10:14
古根海姆维持Adaptive Biotechnologies买入评级 将目标价上调至22美元
古根海姆分析师苏布·南比维持Adaptive Biotechnologies“买入”评级，将其目标价从21美元上调至22美元。 译文内容由第三方软件翻译。 声明...
06-29 22:01
Guggenheim Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $22
Guggenheim analyst Subbu Nambi maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $21 to $22.
06-29 21:56
KB Home Posts Upbeat Q2 Sales, Joins Inmode, Icon And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Nasdaq Composite gaining more than 50 points on Wednesday. Shares of KB Home (NYSE:KBH) rose sharply after the company reported financial results for the second quarter. KB Home reported second-quarter revenue of $1.11 billion, beating analyst estimates of $1.10 bil...
06-24 21:56
Adaptive Biotechnologies Issues Convertible Notes to Reshape Capital
Adaptive Biotechnologies ( ($ADPT) ) has provided an announcement. On June 22, ...
06-23 04:47
Adaptive Biotechnologies发行3.45亿美元2031年到期可转换债券
自适应生物技术公司（ADPT）完成零利息可转换优先票据发行。 核心发行数据： 票据总本金3.45亿美元，2031年7月1日到期，2026年6月22日完成发行...
06-23 04:30
美股大行评级 | 花旗维持美光科技"买入"评级！目标价从840美元升至1200美元
今日重点评级关注：Chardan Capital：维持SAB Biotherapeutics"买入"评级，目标价从14美元升至16美元；Northland Capital Markets：维持Applied Digital"跑赢大市"评级，目标价从56美元升至82美元
06-18 19:08
Adaptive Biotechnologies CSO Harlan S. Robins sells 106,160 shares for $1.85 million
Adaptive Biotechnologies CSO Harlan S. Robins sells 106,160 shares for $1.85 million Adaptive Biotechnologies Chief Scientific Officer Harlan S. Robins sold 106,160 common shares on June 15-16. Sales priced at $17.37, $18.01; holdings fell to 1,405,898 shares. Disclaimer: This news brief was created
06-18 08:11
Adaptive Biotechnologies Business Separation May Unlock Greater Value
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) on Monday announced plans to separate its Minimal Residual Disease (MRD) and Immune Medicine businesses. • Adaptive Biotechnologies stock is trending lower. Why are ADPT shares declining? Adaptive Separation Plan Could Sharpen Focus On MRD Business ...
06-18 01:21
BTIG Reiterates Buy on Adaptive Biotechnologies, Maintains $22 Price Target
BTIG analyst Mark Massaro reiterates Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and maintains $22 price target.
06-17 23:22
